Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

478
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
478
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

540
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
540
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

937
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
937
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

982
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
982
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

838
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
838
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.4K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recommendations for Assessing Methodological Quality in Systematic Reviews of Population Pharmacokinetic Models: A Systematic Review.

Therapeutic drug monitoring·2026
Same author

ITARA research programme: Investigating Integrated Tuberculosis And Respiratory care in Africa using transdisciplinary methods.

BMJ open·2026
Same author

Informing Sampling Design for Lung Distribution Studies Using a Pulmonary Population Minimal PBPK Model.

Clinical pharmacokinetics·2026
Same author

Differential Regulation of Oxidative Burst by First Line Drugs Used Against Multi Drug-Resistant Tuberculosis in Naïve Human Innate Immune Cells.

Antibiotics (Basel, Switzerland)·2026
Same author

Adaptation of a Smartphone-Based Mobile Health Program to Support Person-Centered Treatment of Tuberculosis in Kilimanjaro, Tanzania: Preimplementation Qualitative Needs Assessment.

JMIR formative research·2026
Same author

Transforming health systems in Tanzania towards universal health coverage: a scoping review of policy evolution, 1961-2025.

BMJ open·2026

Related Experiment Video

Updated: Jan 17, 2026

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening
15:28

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening

Published on: January 17, 2014

8.1K

Future Prospects for Using Clinical Phenotypes in Tuberculosis Precision Medicine-An Approach for Clinical

Katarina Niward1,2, Clara Braian2, Gustav Svärdhagen2

  • 1Department of Infectious Diseases, Region Östergötland, Linköping University, Linköping, Sweden.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|January 15, 2026
PubMed
Summary

Shorter tuberculosis treatment requires precise patient phenotyping using

Keywords:
disease severityprecision medicinestratified treatmenttreatment monitoringtuberculosis

More Related Videos

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

81.8K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.3K

Related Experiment Videos

Last Updated: Jan 17, 2026

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening
15:28

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening

Published on: January 17, 2014

8.1K
Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

81.8K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.3K

Area of Science:

  • Tuberculosis research
  • Clinical microbiology
  • Precision medicine

Background:

  • Developing shorter tuberculosis treatment regimens is crucial.
  • Accurate tuberculosis diagnosis and patient stratification are key.
  • Current methods require improvement for personalized treatment.

Purpose of the Study:

  • To outline a strategy for characterizing clinical phenotypes in tuberculosis.
  • To explore the role of advanced 'omics', precision dosing, and AI in tuberculosis treatment.
  • To enhance treatment monitoring for improved patient outcomes.

Main Methods:

  • Characterizing clinical phenotype through patient data, disease extent, bacterial load, drug susceptibility, and host response.
  • Utilizing 'omics' technologies, model-informed precision dosing, and artificial intelligence algorithms.
  • Validating these tools in clinical trials for patient classification and stratified treatment.

Main Results:

  • Integrated monitoring using bacterial load quantification, sputum-free biosignatures (transcriptomic, epigenetic), and radiological/symptom scoring.
  • Adaptation of advanced tools for high-endemic settings.
  • Prompt drug adjustment based on integrated monitoring for rapid bacterial load reduction.

Conclusions:

  • Phenotype-based, stratified treatment with integrated monitoring can enable shorter tuberculosis regimens.
  • This approach facilitates rapid bacterial reduction, preventing drug resistance.
  • Achieving relapse-free cure with shorter treatment durations is feasible.